Utilization of multigene panels in hereditary cancer predisposition testing: Analysis of more than 2,000 patients

Genetics in Medicine

Volumn 16, Issue 11, 2014, Pages 830-837

  Laduca, Holly ^a   Stuenkel, A J ^a   Dolinsky, Jill S ^a   Keiles, Steven ^a   Tandy, Stephany ^a   Pesaran, Tina ^a   Chen, Elaine ^a   Gau, Chia Ling ^a   Palmaer, Erika ^a   Shoaepour, Kamelia ^a   Shah, Divya ^b   Speare, Virginia ^a   Gandomi, Stephanie ^a   Chao, Elizabeth ^a,c  

^a AMBRY GENETICS   (United States)

^b ARCADIA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

hereditary cancer; moderate penetrance genes; multigene panels; next generation sequencing; targeted panels

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COLORECTAL CANCER; COMPUTER PROGRAM; CORRELATION ANALYSIS; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GENETIC DATABASE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; NEXT GENERATION SEQUENCING; OVARY CANCER; PHENOTYPE; SEQUENCE ANALYSIS; UTERUS CANCER; DNA SEQUENCE; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; PENETRANCE; PROCEDURES;

ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; PENETRANCE; SEQUENCE ANALYSIS, DNA;

EID: 84908881428     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.40     Document Type: Article

References (38)

1. Wetterstrand KA. DNA sequencing costs: data from the NHGRI genome sequencing program (GSP). 2013; http://www.genome.gov/sequencingcosts/. Accessed June 2013.
2. ten Bosch JR, Grody WW. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn 2008;10:484-492.
3. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013;5: 189sr184.
4. Rabbani B, Mahdieh N, Hosomichi K, Nakaoka H, Inoue I. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet 2012;57:621-632.
5. Lemke JR, Riesch E, Scheurenbrand T, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 2012;53:1387-1398.
6. Tarpey PS, Smith R, Pleasance E, et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet 2009;41:535-543.
7. Voelkerding KV, Dames S, Durtschi JD. Next generation sequencing for clinical diagnostics-principles and application to targeted resequencing for hypertrophic cardiomyopathy: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2010;12: 539-551.
8. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012;14:357-366.
9. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010;107:12629-12633.
10. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011;108:18032-18037.
11. Castera L, Krieger S, Rousselin A, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet 2014; e-pub ahead of print 19 February 2014.
12. Morgan JE, Carr IM, Sheridan E, et al. Genetic diagnosis of familial breast cancer using clonal sequencing. Hum Mutat 2010;31:484-491.
13. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009;30:197-203.
14. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3 exons of TACSTD1. Nat Genet 2009;41:112-117.
15. Vaughn CP, Baker CL, Samowitz WS, Swensen JJ. The frequency of previously undetectable deletions involving 3 Exons of the PMS2 gene. Genes Chromosomes Cancer 2013;52:107-112.
16. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65.
17. International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-796.
18. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-311.
19. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: 2008 update. Genome Med 2009;1:13.
20. Plon SE, Eccles DM, Easton D, et al.; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-1291.
21. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008;10:294-300.
22. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C->T:A mutations in colorectal tumors. Nat Genet 2002;30:227-232.
23. The NCCN Clinical Practice Guidelines in OncologyTM Genetic/Familial High-Risk Assessment: Breast and Ovarian V1.2014. National Comprehensive Cancer Network. 2014; http://www.nccn.org/. Accessed 3 March 2014.
24. The NCCN Clinical Practice Guidelines in OncologyTM: Colorectal Cancer Screening V1.2013. National Comprehensive Cancer Network. 2013; http://www.nccn.org/. Accessed 4 June 2013.
25. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 2013;31:1267-1270.
26. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med 2013; e-pub ahead of print 10 October 2013.
27. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). 2013. http://evs.gs.washington.edu/EVS/. Accessed June 2013.
28. Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 2013;22:155-163.
29. Spurdle AB, Healey S, Devereau A, et al.; ENIGMA. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012;33:2-7.
30. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
31. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012;2:41-46.
32. Comino-Mndez I, Gracia-Aznrez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011;43:663-667.
33. Palles C, Cazier JB, Howarth KM, et al.; CORGI Consortium; WGS500 Consortium. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45:136-144.
34. Association for Molecular Pathology et al. v. Myriad Genetics, et al. 569 U. S.-(2013); 2013.
35. Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a U.S. laboratory. Clin Genet 2014; e-pub ahead of print 9 February 2014.
36. Sweet K, Willis J, Zhou XP, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005;294:2465-2473.
37. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009;16: 405-417.
38. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008;10:293-300.